Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope
Pays $800m Upfront For Gene Therapy Eye Specialist
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.
You may also be interested in...
Cambridge Innovation Capital partner Robert Tansley tells Scrip that the UK has "a really strong history of innovation in biological sciences and Cambridge has been at the forefront” but this has not equated to a substantial number of biotech companies “where we have lagged significantly behind the US."
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.
The Swiss giant has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.